Peter J. O’Dwyer

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I

  JCO Precision Oncology · 2026-06-01

• Supplementary Figure 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Supplementary Figure 2 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Supplementary Figure 3 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Supplementary Data 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Supplementary Table 2 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Supplementary Table 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Data from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Supplementary Table 3 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Supplementary Table S1 from Phase II Study of Palbociclib (PD-0332991) in <i>CCND1</i>, <i>2</i>, or <i>3</i> Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

  2025-11-25

• supplementary table TS1 from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

  2025-11-25

• Treatment-related toxicities and functional outcomes in vulnerable older adults with metastatic pancreatic cancer: Analysis from ECOG-ACRIN EA2186

  Journal of Geriatric Oncology · 2025-11-01

• Supplementary Table 3 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

  2025-10-15

• Supplementary Figure 7 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)Preprint

  2025-10-15

• Supplementary Table 1 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

  2025-10-15

• Supplementary Table 5 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

  2025-10-15

• Supplementary Table 9 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

  2025-10-15

• Supplementary Figure 4 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)Preprint

  2025-10-15

• Supplementary Figure 3 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)Preprint

  2025-10-15

• Supplementary Figure 5 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)Preprint

  2025-10-15